New DESTINY-Breast06 analysis showed trastuzumab deruxtecan doubled PFS versus chemotherapy in patients with rapid ...

A phase 2 trial showed ctDNA detection in HR-positive early breast cancer was linked to larger tumors, higher residual cancer ...

Patients with advanced estrogen receptor (ER)-positive breast cancer that progressed on CDK4/6 inhibitors had better survival ...

machine learning and AI for data integration and novel biomarker and drug target discoveries. RE-MEND will combine the general population-based studies and clinical studies to define the genetic and ...

Alisertib, an Aurora A kinase inhibitor, is combined with endocrine therapy to assess response rates, disease control, and survival metrics. Secondary study goals involve biomarker subgroup analysis, ...

Targeting the estrogen receptor and HER2 pathways improved progression-free survival in patients with HR-positive, ...

Results of the a phase III clinical trial called EMBER-3 indicate the promise and efficacy of a drug called imlunestrant. This is a new kind of oral selective estrogen receptor degrader (SERD), used ...